PAIN
Volume 151, Issue 2 , Pages 554-555 , November 2010

Response to Drs. Bell and Moore commentary regarding the use of intravenous ketamine for CRPS

Received 15 July 2010 ,Accepted 14 August 2010.

References 

  1. Bell RF, Moore RA. Intravenous ketamine for CRPS: making too much of too little?. Pain. 2010;150:10–11
  2. Curran HV, Monaghan L. In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction. 2001;96:749–760
  3. Kiefer RT, Rohr P, Ploppa A, Dieterich HJ, Grothusen J, Koffler S, et al. Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study. Pain Med. 2008;9:1173–1201
  4. Koffler SP, Hampstead BM, Irani F, Tinker J, Kiefer RT, Rohr P, et al. The neurocognitive effects of 5 day anesthetic ketamine for the treatment of refractory complex regional pain syndrome. Arch Clin Neuropsychol. 2007;22:719–729
  5. Narendran R, Frankle WG, Keefe R, Gil R, Martinez D, Slifstein M, et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry. 2005;162:2352–2359
  6. Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain. 2009;147:107–115

PII: S0304-3959(10)00486-0

doi: 10.1016/j.pain.2010.08.018

PAIN
Volume 151, Issue 2 , Pages 554-555 , November 2010

Article Tools